All In Biotech

Drug Trial Radar · NCT04543331

Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema

OBservationaL stUdy to Evaluate Fluid reSolution and Effectiveness in Patients Receiving Beovu (Brolucizumab) Under KeY Treatment Schemes in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

572

Actual

Start

Mar 18, 2020

Primary completion

Nov 17, 2025

Study completion Nov 17, 2025

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Sep 10, 2020

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was a prospective, non-interventional, multicenter, open-label study in nAMD and DME patients being treated with brolucizumab according to the EU SmPC. An observational study design, without a strict, mandated visit schedule or mandated treatment regimen was chosen as the most appropriate to collect available data in a real life setting. For that reason, this NIS did not impose a therapy protocol, diagnostic/therapeutic procedure or a visit schedule. The diagnostic or monitoring procedures were only those ordinarily applied to the therapeutic strategy and to routine clinical care and took place as per investigator's discretion. This included e.g. visit frequency, injection frequency and types of assessments performed - only data from routine medical practice was collected as part of the study.

Conditions

  • Neovascular Age-related Macular Degeneration (nAMD)
  • Diabetic Macular Edema (DME)

Interventions

  • brolucizumabDrug

    There was no treatment allocation. Patients administered Brolucizumab by prescription that had started before inclusion of the patient into the study were enrolled.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patients' eyes that are absent of subretinal fluid (SRF) and intra-retinal fluid (IRF)Time frame: Month 12
  2. Mean change in visual acuity (VA) under clinic specific routine treatment schemesTime frame: Baseline, month 12
  3. Morphological CNV-Changes under clinic specific routine treatment schemesTime frame: Baseline, month 12
  4. Percent of patients maintained on q12w dosing after loading through Week 52Time frame: After loading, month 12
  5. Change in interval length from last interval before switch (baseline) to last interval at end of follow-up (12 months)Time frame: Baseline, month 12

Locations

41 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Aschersleben, Germany

  • Novartis Investigative Site

    Bayreuth, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Bonn, Germany

  • Novartis Investigative Site

    Breisach, Germany

  • Novartis Investigative Site

    Chemnitz, Germany

  • Novartis Investigative Site

    Cologne, Germany

  • Novartis Investigative Site

    Dresden, Germany

  • Novartis Investigative Site

    Dresden, Germany

  • Novartis Investigative Site

    Esslingen am Neckar, Germany

  • Novartis Investigative Site

    Glauchau, Germany

  • Novartis Investigative Site

    Homburg, Germany

  • Novartis Investigative Site

    Hösbach, Germany

  • Novartis Investigative Site

    Kiel, Germany

  • Novartis Investigative Site

    Leipzig, Germany

  • Novartis Investigative Site

    Magdeburg, Germany

  • Novartis Investigative Site

    Marienberg, Germany

  • Novartis Investigative Site

    Münster, Germany

  • Novartis Investigative Site

    Neubrandenburg, Germany

  • Novartis Investigative Site

    Schönebeck, Germany

  • Novartis Investigative Site

    Stralsund, Germany

  • Novartis Investigative Site

    Sulzbach, Germany

  • Novartis Investigative Site

    Torgau, Germany

  • Novartis Investigative Site

    Waren, Germany

  • Novartis Investigative Site

    Würzburg, Germany

  • Novartis Investigative Site

    Munich, Bavaria, Germany

  • Novartis Investigative Site

    Neuburg A.d. Donau, Bavaria, Germany

  • Novartis Investigative Site

    Würzburg, Bavaria, Germany

  • Novartis Investigative Site

    Würzburg, Bavaria, Germany

  • Novartis Investigative Site

    Frankfurt am Main, Hesse, Germany

  • Novartis Investigative Site

    Göttingen, Lower Saxony, Germany

  • Novartis Investigative Site

    Osnabrück, Lower Saxony, Germany

  • Novartis Investigative Site

    Rostock, Mecklenburg-Vorpommern, Germany

  • Novartis Investigative Site

    Trier, Rhineland-Palatinate, Germany

  • Novartis Investigative Site

    Saarbrücken, Saarland, Germany

  • Novartis Investigative Site

    Dresden, Saxony, Germany

  • Novartis Investigative Site

    Leipzig, Saxony, Germany

  • Novartis Investigative Site

    Schneeberg, Saxony, Germany

  • Novartis Investigative Site

    Halle, Saxony-Anhalt, Germany

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.